[Executive Summary & Business Update](index=1&type=section&id=Executive%20Summary%20%26%20Business%20Update) This section provides an overview of Cartesian Therapeutics' recent pipeline advancements, anticipated milestones, and detailed descriptions of its lead product candidates, Descartes-08 and Descartes-15 - Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in **2Q25**[1](index=1&type=chunk)[3](index=3&type=chunk) - Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected in **2H25**[1](index=1&type=chunk)[9](index=9&type=chunk) - Initiation of Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications expected in **2H25**[1](index=1&type=chunk)[9](index=9&type=chunk) [Recent Pipeline Progress and Anticipated Milestones](index=1&type=section&id=Recent%20Pipeline%20Progress%20and%20Anticipated%20Milestones) Cartesian Therapeutics reported significant pipeline advancements, including positive long-term Phase 2b results for Descartes-08 in myasthenia gravis (MG) and the planned initiation of the Phase 3 AURORA trial in Q2 2025 [Descartes-08 in Myasthenia Gravis (MG)](index=1&type=section&id=Descartes-08%20in%20Myasthenia%20Gravis%20(MG)) Updated long-term results from the Phase 2b trial of Descartes-08 in MG showed deep and sustained benefits through 12 months after a single course of therapy, particularly in participants without prior biologic exposure - Positive updated long-term results from Phase 2b trial of Descartes-08 in MG, with sustained benefits observed through **12 months** after a single course of therapy[3](index=3&type=chunk) - Average **4.8-point reduction** in MG Activities of Daily Living Scale (MG-ADL) at Month 12 for Descartes-08-treated participants[3](index=3&type=chunk) - Initiation of Phase 3 AURORA Trial of Descartes-08 in MG on track for **2Q25**, designed to assess Descartes-08 versus placebo in approximately **100 participants**[3](index=3&type=chunk) [Descartes-08 in Systemic Lupus Erythematosus (SLE)](index=2&type=section&id=Descartes-08%20in%20Systemic%20Lupus%20Erythematosus%20(SLE)) Preliminary data from the ongoing Phase 2 open-label trial of Descartes-08 in patients with SLE is expected in the second half of 2025, assessing safety, tolerability, and clinical activity of outpatient Descartes-08 administration without preconditioning chemotherapy - Preliminary data from ongoing Phase 2 open-label trial of Descartes-08 in patients with SLE expected in the **second half of 2025**[9](index=9&type=chunk) - The trial assesses safety, tolerability, and clinical activity of outpatient Descartes-08 administration without preconditioning chemotherapy[9](index=9&type=chunk) [Descartes-08 Pediatric Basket Trial](index=2&type=section&id=Descartes-08%20Pediatric%20Basket%20Trial) A Phase 2 pediatric basket trial of Descartes-08 in select autoimmune diseases, including juvenile SLE, juvenile MG, juvenile dermatomyositis (JDM), and anti-neutrophil cytoplasmic antibody associated vasculitis, is expected to initiate in the second half of 2025 - Phase 2 Pediatric Basket Trial of Descartes-08 in select autoimmune diseases expected to initiate in the **second half of 2025**[9](index=9&type=chunk) - This trial will target juvenile SLE, juvenile MG, juvenile dermatomyositis (JDM) and anti-neutrophil cytoplasmic antibody associated vasculitis[9](index=9&type=chunk) - The FDA previously granted Rare Pediatric Disease Designation to Descartes-08 for the treatment of JDM[9](index=9&type=chunk) [Descartes-15 Development](index=2&type=section&id=Descartes-15%20Development) Dosing continues in the first-in-human Phase 1 clinical trial of Descartes-15 for multiple myeloma, with plans to subsequently assess this next-generation CAR-T cell therapy in autoimmune indications - Dosing continues in First-in-Human Phase 1 Clinical Trial of Descartes-15 for multiple myeloma[9](index=9&type=chunk) - The Company expects to subsequently assess Descartes-15 in autoimmune indications after the Phase 1 dose escalation trial[9](index=9&type=chunk) [Product Candidate Overviews](index=2&type=section&id=Product%20Candidate%20Overviews) Cartesian Therapeutics is developing two key autologous CAR-T cell therapy candidates, Descartes-08 and Descartes-15, both designed for outpatient administration without preconditioning chemotherapy and without the risk of genomic integration [About Descartes-08](index=2&type=section&id=About%20Descartes-08) Descartes-08 is Cartesian's lead autologous anti-BCMA CAR-T cell therapy candidate, in clinical development for generalized myasthenia gravis (MG) and systemic lupus erythematosus (SLE), and has received multiple FDA designations - Descartes-08 is an autologous chimeric antigen receptor T-cell therapy (CAR-T) product targeting B-cell maturation antigen (BCMA)[6](index=6&type=chunk) - Designed to not require preconditioning chemotherapy, can be administered in the outpatient setting, and does not carry the risk of genomic integration[6](index=6&type=chunk) - Granted Orphan Drug Designation, Regenerative Medicine Advanced Therapy Designation for MG, and Rare Pediatric Disease Designation for juvenile dermatomyositis[6](index=6&type=chunk) [About Descartes-15](index=2&type=section&id=About%20Descartes-15) Descartes-15 is a next-generation, autologous anti-BCMA CAR-T cell therapy that has shown an approximately ten-fold increase in CAR expression and selective target-specific killing in preclinical studies compared to Descartes-08, sharing its design benefits - Descartes-15 is a next-generation, autologous anti-BCMA CAR-T cell therapy[7](index=7&type=chunk) - In preclinical studies, Descartes-15 achieved an approximately **ten-fold increase** in CAR expression and selective target-specific killing, relative to Descartes-08[7](index=7&type=chunk) - Designed to be administered without preconditioning chemotherapy and does not use integrating vectors[7](index=7&type=chunk) [First Quarter 2025 Financial Results](index=2&type=section&id=First%20Quarter%202025%20Financial%20Results) This section details Cartesian Therapeutics' financial performance for the first quarter of 2025, including key financial highlights, balance sheet figures, and statements of operations [Financial Highlights](index=2&type=section&id=Financial%20Highlights) Cartesian Therapeutics reported a cash position of $182.1 million as of March 31, 2025, expected to fund operations into mid-2027, with increased R&D expenses and a substantially improved net loss per share - Cash, cash equivalents and restricted cash as of March 31, 2025 was **$182.1 million**, expected to support planned operations into **mid-2027**[1](index=1&type=chunk)[9](index=9&type=chunk) Key Financial Highlights (Q1 2025 vs Q1 2024) | Metric | Q1 2025 (in millions) | Q1 2024 (in millions) | Change (YoY) (in millions) | | :-------------------------------- | :-------------------- | :-------------------- | :----------- | | Research and development expenses | $14.7 | $9.7 | +$5.0 | | General and administrative expenses | $8.3 | $9.5 | -$1.2 | | Net loss | $(17.7) | $(56.8) | +$39.1 | | Net loss per share (basic) | $(0.68) | $(10.50) | +$9.82 | [Consolidated Balance Sheets](index=5&type=section&id=Consolidated%20Balance%20Sheets) As of March 31, 2025, Cartesian Therapeutics reported total assets of $409.1 million, a decrease from $435.0 million at December 31, 2024, primarily due to reduced cash and cash equivalents, alongside decreased total liabilities and an increased stockholders' deficit Consolidated Balance Sheet Highlights (Amounts in thousands) | Metric | March 31, 2025 (Unaudited) | December 31, 2024 | | :------------------------------------ | :------------------------- | :---------------- | | Cash and cash equivalents | $180,434 | $212,610 | | Total current assets | $185,120 | $216,626 | | Total assets | $409,130 | $435,023 | | Total current liabilities | $14,998 | $22,976 | | Total liabilities | $430,919 | $441,825 | | Total stockholders' deficit | $(21,789) | $(6,802) | [Consolidated Statements of Operations and Comprehensive Loss](index=6&type=section&id=Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) For the three months ended March 31, 2025, total revenue decreased significantly to $1.1 million from $5.8 million in the prior year, primarily due to lower collaboration and license revenue, while operating expenses increased, leading to a reduced net loss of $(17.7) million compared to $(56.8) million in Q1 2024 due to a positive change in contingent value right liability Consolidated Statements of Operations Highlights (Amounts in thousands) | Metric | Three Months Ended March 31, 2025 (Unaudited) | Three Months Ended March 31, 2024 | | :------------------------------------------ | :-------------------------------------------- | :-------------------------------- | | Collaboration and license revenue | $400 | $5,840 | | Grant revenue | $700 | $— | | Total revenue | $1,100 | $5,840 | | Research and development | $14,674 | $9,738 | | General and administrative | $8,315 | $9,450 | | Total operating expenses | $22,989 | $19,188 | | Operating loss | $(21,889) | $(13,348) | | Change in fair value of contingent value right liability | $346 | $(39,300) | | Net loss | $(17,710) | $(56,824) | | Basic and diluted net loss per share | $(0.68) | $(10.50) | [About Cartesian Therapeutics](index=2&type=section&id=About%20Cartesian%20Therapeutics) Cartesian Therapeutics is a clinical-stage biotechnology company focused on pioneering cell therapy for autoimmune diseases, with its lead asset, Descartes-08, entering Phase 3 for generalized myasthenia gravis and Phase 2 for systemic lupus erythematosus, and Descartes-15 in Phase 1 development for multiple myeloma - Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases[1](index=1&type=chunk)[10](index=10&type=chunk) - The Company's lead asset, Descartes-08, is a CAR-T entering **Phase 3** clinical development for generalized myasthenia gravis and **Phase 2** development for systemic lupus erythematosus[10](index=10&type=chunk) - The clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a **Phase 1 trial** in patients with multiple myeloma[10](index=10&type=chunk) [Forward Looking Statements](index=4&type=section&id=Forward%20Looking%20Statements) This section contains standard forward-looking statements regarding the company's future expectations, plans, and prospects, including clinical trial outcomes, regulatory approvals, and financial resources, emphasizing that actual results may differ materially due to various important factors and risks - Statements about future expectations, plans and prospects, including cash resources, product candidate administration, potential to treat diseases, and timing/outcome of clinical trials, constitute forward-looking statements[11](index=11&type=chunk) - Actual results may differ materially due to various important factors, including uncertainties in clinical trials, data availability, regulatory approvals, funding, and other risks discussed in SEC filings[11](index=11&type=chunk) - The Company specifically disclaims any intention to update any forward-looking statements, except as required by law[11](index=11&type=chunk) [Contact Information](index=7&type=section&id=Contact%20Information) This section provides contact details for investor and media inquiries - Investor Contact: Megan LeDuc, Associate Director of Investor Relations (megan.leduc@cartesiantx.com)[16](index=16&type=chunk) - Media Contact: David Rosen, Argot Partners (david.rosen@argotpartners.com)[16](index=16&type=chunk)

Core Insights - Cartesian Therapeutics is advancing its lead product candidate, Descartes-08, with significant milestones expected in 2025, including the initiation of a Phase 3 trial for myasthenia gravis (MG) and preliminary data from a Phase 2 trial for systemic lupus erythematosus (SLE) [1][2][3] Pipeline Progress - The Phase 2b trial of Descartes-08 in MG showed deep and sustained benefits, with a 4.8-point reduction in the MG Activities of Daily Living Scale (MG-ADL) at Month 12 after a single therapy course [3] - In participants without prior exposure to biologic therapies, there was a 7.1-point reduction in MG-ADL, with 57% maintaining minimal symptoms at Month 12 [3] - The Phase 3 AURORA trial is set to begin in Q2 2025, involving approximately 100 participants and assessing the efficacy of Descartes-08 compared to placebo [3] Financial Overview - As of March 31, 2025, the company reported approximately $182.1 million in cash and equivalents, expected to fund operations through mid-2027 [1][8] - Research and development expenses for Q1 2025 were $14.7 million, up from $9.7 million in Q1 2024, primarily due to increased trial activities [8] - The net loss for Q1 2025 was $(17.7) million, a significant reduction from $(56.8) million in the same period of 2024, with a net loss per share of $(0.68) compared to $(10.50) [8][14] Future Trials - Preliminary data from the ongoing Phase 2 trial of Descartes-08 in SLE is anticipated in the second half of 2025 [1][8] - A Phase 2 pediatric basket trial targeting juvenile autoimmune diseases is also expected to initiate in the second half of 2025 [1][8]

Core Insights - Cartesian Therapeutics announced positive 12-month efficacy and safety data from the Phase 2b trial of Descartes-08 for generalized myasthenia gravis (MG), showing sustained symptom improvement in participants [2][4][9] - Descartes-08 demonstrated a significant average reduction in MG-ADL scores, particularly in patients without prior biologic therapy, indicating its potential as a transformative treatment option [9][11] Efficacy Results - Participants treated with Descartes-08 experienced an average MG-ADL reduction of 4.8 points at Month 12, with deeper responses observed over time [7][11] - In the subgroup of participants without prior biologic therapy, the average MG-ADL reduction was 7.1 points at Month 12, with 57% maintaining minimum symptom expression [11] - 83% of evaluable participants maintained a clinically meaningful response through Month 12, defined as a reduction of at least 2 points in MG-ADL [7] Safety Profile - The safety profile of Descartes-08 was consistent with previously reported data, supporting its outpatient administration without the need for preconditioning chemotherapy [4][10] - Adverse events were mostly mild and transient, with no new adverse events reported during the 12-month follow-up [10][11] Future Development - The Phase 3 AURORA trial is on track to dose the first patient in the second quarter of 2025, with the trial design accepted by the FDA under the Special Protocol Assessment process [9][14] - Descartes-08 has received Regenerative Medicine Advanced Therapy and Orphan Drug Designations from the FDA, highlighting its potential in treating MG [9][13]

Core Insights - Cartesian Therapeutics announced positive 12-month efficacy and safety data from the Phase 2b trial of Descartes-08 for generalized myasthenia gravis (MG) [2][4] - Descartes-08 demonstrated sustained symptom improvement with an average reduction of 4.8 points in MG Activities of Daily Living (MG-ADL) at Month 12 [6][8] - The therapy showed particularly strong results in participants without prior exposure to biologic therapies, achieving an average 7.1-point reduction in MG-ADL [10] Efficacy Results - In the Phase 2b trial, participants receiving Descartes-08 experienced deep responses, with an average MG-ADL reduction of 5.5 at Month 4 and 4.8 at Month 12 [6][4] - 83% of evaluable participants maintained a clinically meaningful response through Month 12, defined as a reduction of at least 2 points in MG-ADL [6] - Among participants without prior biologic therapy, 100% maintained a clinically meaningful response through Month 12 [10] Safety Profile - Descartes-08 was well-tolerated, with no new adverse events reported during the 12-month follow-up [10] - Common side effects included transient infusion-related reactions such as fever (60%), chills (60%), headache (55%), and nausea (45%), all resolving within 24 hours [10] - No cases of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) were reported [10] Future Developments - The Phase 3 AURORA trial is set to dose the first patient in the second quarter of 2025, following FDA agreement on the trial design [8][10] - Descartes-08 has received Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designations from the FDA for the treatment of MG [12][8] - The company aims to transform the treatment landscape for MG with Descartes-08, offering a safe and durable outpatient therapy option [8][10]

Core Insights - Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company focused on mRNA cell therapies for autoimmune diseases [3] - The company will participate in the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025 [1] Company Overview - Cartesian Therapeutics is pioneering mRNA CAR-T therapies, with its lead asset Descartes-08 entering Phase 3 clinical development for generalized myasthenia gravis and Phase 2 for systemic lupus erythematosus [3] - Descartes-08 has received FDA agreement under the Special Protocol Assessment for its Phase 3 trial [3] - The company also has Descartes-15, an autologous anti-BCMA mRNA CAR-T in Phase 1 trial for multiple myeloma [3] Event Information - A live webcast of the conference presentation will be available on the company's website, along with an archived replay for a limited time [2]

Clinical Trials and Efficacy - The company reported an average MG-ADL reduction of 5.5 points at Month 4 in a Phase 2b trial for myasthenia gravis, with 80% of participants maintaining a clinically meaningful response at Month 12[17]. - In the Phase 2b trial, 71% of patients treated with Descartes-08 showed a 5-point or greater improvement in MG Composite score at Month 3 compared to 25% in the placebo group (p=0.018)[25]. - The Phase 2a trial results indicated that 33% of participants without prior biologic therapy achieved minimum symptom expression at Month 6[27]. - After six weekly infusions of Descartes-08, patients showed an average MG-ADL reduction of 5.5 points and an average MGC reduction of 7.1 points, both exceeding clinically meaningful thresholds[60]. - 80% of participants who reached Month 12 maintained clinically meaningful responses, with 57% of those with no prior exposure to biologic therapy achieving minimal symptom expression at Month 6[63]. - The Phase 1/2 trial of Descartes-08 in MG has shown it to be well-tolerated, with no serious product-related adverse events reported[54]. - The most common product-related adverse events were headache (35%), chills (40%), and fever (35%), all of which were self-limited[65]. - The company is also developing Descartes-08 for systemic lupus erythematosus, with a data readout expected in the second half of 2025[32]. - A multi-center open-label Phase 2 trial for Descartes-08 in systemic lupus erythematosus (SLE) has been initiated, with preliminary data expected in the second half of 2025[68]. Regulatory Designations and Approvals - Descartes-08 has received Orphan Drug Designation and RMAT Designation from the FDA for the treatment of myasthenia gravis, as well as Rare Pediatric Disease Designation for juvenile dermatomyositis[24]. - The FDA granted a priority review voucher program for Descartes-08 if approved for juvenile dermatomyositis, which could expedite future marketing applications[33]. - Descartes-08 has received Orphan Drug Designation and RMAT Designation for the treatment of Myasthenia Gravis (MG)[117]. - Descartes-08 has also received RMAT designation, facilitating an efficient development program for the treatment of MG[123]. - The FDA requires a Biologics License Application (BLA) to include results from product development, laboratory and animal trials, human trials, and manufacturing information before commercial marketing can begin[108]. - The FDA aims to review 90% of standard BLAs within 10 months and 90% of priority BLAs within 6 months from the filing date[113]. - The FDA may impose clinical holds on a biological product candidate at any time due to safety concerns or non-compliance with regulatory requirements[98]. - The FDA requires safety and efficacy to be demonstrated in two adequate and well-controlled clinical trials before approving new therapeutic products[179]. Manufacturing and Development - The main manufacturing facility is located in Frederick, Maryland, which has sufficient capacity to support current clinical needs and can transition to commercial manufacturing of mRNA cell therapies[71]. - Descartes-08 is manufactured in-house, with the ability to process and release lots for infusion within approximately three weeks, optimized through over 200 cGMP runs[72]. - The company is expanding its manufacturing capabilities, incurring significant costs, and may need to rely on third-party manufacturers[202]. - Manufacturing challenges, including reliance on third-party laboratories for quality control, could delay clinical trials and increase expenses[204]. - The company must comply with FDA and foreign regulatory authority requirements for manufacturing, and failure to do so could delay regulatory approvals[207]. Financial and Market Considerations - The company expects to incur losses for the foreseeable future and may never achieve profitability[171]. - Coverage and reimbursement for pharmaceutical products depend on third-party payors, including government authorities and private insurers, impacting sales post-regulatory approval[152]. - The company may face challenges in achieving sufficient market acceptance, which is critical for generating significant product revenues and profitability[215]. - The company must effectively compete with other therapies and ensure adequate reimbursement from third-party payors for its products[28]. - The company is subject to various risks, including stockholder litigation and challenges in protecting proprietary technology[171]. - The Inflation Reduction Act of 2022 may significantly affect the pharmaceutical industry, potentially reducing prices and reimbursement rates for approved products[159]. - The EU's health technology assessment regulation may complicate pricing negotiations and reimbursement approvals for the company's products[155]. - The company anticipates that political, economic, and regulatory developments may further complicate pricing negotiations in the EU[156]. Competitive Landscape - The biotechnology industry is characterized by intense competition, with potential competitors having greater financial resources and established market presence[87]. - Descartes-08 may compete with products from companies like Argenx SE and Johnson & Johnson in the MG market[90]. - The company regards its mRNA-modified products as cell therapy products, subject to regulation as "biologics" in the U.S.[93]. Risks and Challenges - The company may face increased product development costs due to delays in clinical testing or obtaining marketing approvals[182]. - Delays in clinical trials could result from various factors, including unfavorable results, safety concerns, or inability to recruit suitable patients[180]. - Undesirable side effects from product candidates could lead to regulatory delays or market acceptance issues if approved[192]. - The company faces significant risks related to drug-related side effects that could impact patient enrollment and completion of clinical trials, potentially harming its business and financial condition[196]. - If product candidates receive marketing approval but later show undesirable side effects, it could lead to market acceptance issues and significantly harm business prospects[197]. - Inadequate funding for the FDA may hinder its ability to review and approve new products, affecting the company's operations and regulatory submissions[198]. - Disruptions at the FDA could increase the time required for drug approvals, adversely affecting the company's business[199]. - The company has not yet demonstrated the ability to successfully complete any Phase 3 clinical trials or obtain regulatory approvals[171]. Intellectual Property - As of December 31, 2024, the company holds seven issued patents worldwide, with expiration dates ranging from 2040 to 2044, and has 13 pending patent applications[73]. - The company may experience challenges in maintaining patent protection and regulatory exclusivity for its product candidates[28].

Financial Performance - The net loss for the year ended December 31, 2024, was $(77.4) million, or $(4.48) net loss per share, compared to a net loss of $(219.7) million, or $(49.76) net loss per share in 2023[10]. - Total revenue for the year ended December 31, 2024, was $38,913,000, representing a 49% increase from $26,004,000 in 2023[19]. - The operating loss narrowed to $43,897,000 in 2024 from $86,416,000 in 2023, reflecting a reduction of approximately 49%[19]. - The company reported a change in fair value of contingent value right liability of $(36,900,000) in 2024, compared to $(18,300,000) in 2023, indicating increased liability[19]. Expenses - Research and development expenses for the year ended December 31, 2024, were $45.1 million, a decrease from $71.3 million in 2023, primarily due to restructuring and strategic reprioritization[9]. - General and administrative expenses decreased to $30.1 million for the year ended December 31, 2024, down from $40.5 million in 2023, attributed to reductions in stock compensation and professional fees related to the merger[9]. - Research and development expenses decreased to $45,105,000 in 2024 from $71,260,000 in 2023, a reduction of approximately 37%[19]. - General and administrative expenses also decreased to $30,126,000 in 2024 from $40,450,000 in 2023, a decline of about 26%[19]. Cash and Assets - As of December 31, 2024, Cartesian Therapeutics reported approximately $214.3 million in cash, cash equivalents, and restricted cash, expected to support operations into mid-2027, including the completion of the Phase 3 AURORA trial[2][9]. - Cash and cash equivalents increased significantly to $212,610,000 as of December 31, 2024, compared to $76,911,000 in 2023, marking a growth of 176%[17]. - Total assets rose to $435,023,000 in 2024 from $305,050,000 in 2023, an increase of about 42%[17]. - Total current liabilities decreased to $22,976,000 in 2024 from $68,209,000 in 2023, a reduction of approximately 66%[17]. Clinical Trials and Developments - The Phase 3 AURORA trial of Descartes-08 in myasthenia gravis is set to commence in the first half of 2025, with a primary endpoint assessing improvement in MG Activities of Daily Living (MG-ADL) score[4][3]. - Preliminary data from the ongoing Phase 2 trial of Descartes-08 in systemic lupus erythematosus is expected in the second half of 2025[8]. - The Phase 2 pediatric basket trial of Descartes-08 in select autoimmune diseases is anticipated to initiate in the second half of 2025[8]. - The Phase 2b trial of Descartes-08 in myasthenia gravis showed an average MG-ADL reduction of 5.5 at Month 4, with 80% of evaluable participants maintaining a clinically meaningful response through Month 12[5][4]. - Dosing is currently underway in the first-in-human Phase 1 trial of Descartes-15, a next-generation mRNA CAR-T therapy targeting multiple myeloma[8]. - Cartesian Therapeutics has received written agreement from the FDA under the Special Protocol Assessment process for the Phase 3 AURORA trial design, indicating a clear path toward potential approval[4][3]. Shareholder Information - The weighted-average common shares outstanding increased to 17,276,822 in 2024 from 5,170,319 in 2023, reflecting a significant increase in share issuance[19].

Core Insights - Cartesian Therapeutics is advancing its mRNA cell therapy pipeline, particularly focusing on Descartes-08 for autoimmune diseases, with significant progress expected in 2025 [3][4][13] Pipeline Progress and Milestones - The Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) is set to commence in the first half of 2025, with a design approved by the FDA under the Special Protocol Assessment (SPA) [4][11] - The trial will involve approximately 100 participants and aims to assess the efficacy of Descartes-08 compared to placebo, focusing on improvements in MG Activities of Daily Living (MG-ADL) scores [4] - Positive results from the Phase 2b trial of Descartes-08 showed an average MG-ADL reduction of 5.5 points at Month 4, with 80% of participants maintaining a clinically meaningful response at Month 12 [4][10] - Ongoing Phase 2 trials for Descartes-08 in systemic lupus erythematosus (SLE) are expected to yield preliminary data in the second half of 2025, alongside a planned Phase 2 pediatric basket trial targeting various autoimmune conditions [3][4][9] Financial Overview - As of December 31, 2024, the company reported approximately $214.3 million in cash and equivalents, expected to support operations through mid-2027 [2][10] - Research and development expenses decreased to $45.1 million in 2024 from $71.3 million in 2023, attributed to restructuring and strategic reprioritization [10][20] - The net loss for 2024 was $(77.4) million, a significant reduction from $(219.7) million in 2023, reflecting improved financial management [10][21] Corporate Updates - Emily English has been promoted to Chief Operations Officer, contributing to the expansion of the company's manufacturing capabilities [6] - Cartesian Therapeutics continues to focus on outpatient administration of its therapies, eliminating the need for preconditioning chemotherapy, which is a significant advantage over traditional CAR-T therapies [11][12]

Company Overview - Cartesian Therapeutics is a clinical-stage biotechnology company focused on pioneering mRNA cell therapies for autoimmune diseases [2] - The lead asset, Descartes-08, is in Phase 2b clinical development for generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with plans for a Phase 2 basket trial in additional autoimmune indications [2] - The clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T [2] Upcoming Events - The company management is scheduled to participate in several investor conferences in February and March 2025, including: - A fireside chat at the H.C. Wainright & Co. 3rd Annual Cell Therapy Virtual Conference on February 25, 2025 [3] - A presentation at the TD Cowen 45th Annual Health Care Conference on March 3, 2025, in Boston, MA [3] - A fireside chat at the Leerink Global Healthcare Conference on March 10, 2025, in Miami, FL [3] - Live webcasts of these presentations will be accessible on the company's website, with archived replays available for a limited time [1]

Core Viewpoint - Cartesian Therapeutics has received FDA agreement on the Phase 3 AURORA trial design for its mRNA cell therapy candidate Descartes-08, aimed at treating myasthenia gravis (MG), indicating a clear path toward potential approval [1][2] Company Overview - Cartesian Therapeutics is a clinical-stage biotechnology company focused on mRNA cell therapy for autoimmune diseases, with its lead asset Descartes-08 in development for generalized myasthenia gravis and systemic lupus erythematosus [6] Trial Details - The Phase 3 AURORA trial will be a randomized, double-blind, placebo-controlled study involving approximately 100 participants with acetylcholine receptor autoantibody positive MG, assessing the efficacy of Descartes-08 compared to placebo [2][3] - The primary endpoint of the trial is to evaluate the proportion of participants showing a three-point or greater improvement in the MG Activities of Daily Living (MG-ADL) score at Month 4 [2] Previous Results - Positive results from the Phase 2b trial indicated that participants treated with Descartes-08 experienced an average MG-ADL reduction of 5.5 (±1.1) at Month 4, demonstrating deep and durable improvements [3] Treatment Characteristics - Descartes-08 is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy that does not require preconditioning chemotherapy and can be administered in an outpatient setting, reducing risks associated with conventional therapies [5] - The therapy has received Orphan Drug Designation and Regenerative Medicine Advanced Therapy Designation from the FDA for treating MG [5] Disease Context - Myasthenia gravis is a chronic autoimmune disorder characterized by muscle weakness and fatigue, with no current cure available, necessitating chronic immunosuppressive treatments that carry risks and side effects [4]